Overview

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Status:
Recruiting
Trial end date:
2025-10-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetic (PK) properties of antiretroviral (ARV) and anti-tuberculosis (TB) drugs administered during pregnancy and postpartum.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Gilead Sciences
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network
Merck Sharp & Dohme Corp.
National Institute of Mental Health (NIMH)
ViiV Healthcare
Treatments:
Atazanavir Sulfate
Cabotegravir
Cobicistat
Darunavir
Dolutegravir
Lopinavir
Ritonavir
Tenofovir